BACKGROUND AND OBJECTIVES: Delineation of adequate tumor margins is critical in oncologic surgery, particularly in resection of metastatic lesions. Surgeons are limited in visualization with bright-light surgery, but fluorescence-guided surgery (FGS) has been efficacious in helping the surgeon achieve negative margins. METHODS: The present study uses FGS in a mouse model that has undergone surgical orthotopic implantation (SOI) of colorectal liver metastasis tagged with green fluorescent protein (GFP). An anti-CEA antibody conjugated to DyLight 650 was used to highlight the tumor. RESULTS: The fluorescent antibody clearly demarcated the lesion at deeper tissue depth compared to GFP. Fluorescence of the anti-CEA-DyLight650 showed maximal tumor-to-liver contrast at 72 hr. Fifteen mice underwent bright-light surgery (BLS) versus FGS with GFP versus FGS with anti-CEA-DyLight650. Mice that underwent FGS had a significantly smaller area of residual tumor (P < 0.001) and significantly longer overall survival (P < 0.001) and disease-free survival (P < 0.001). Within the two FGS groups, mice undergoing surgery with anti-CEA-DyLight650 improved survival compared to only GFP labeling. CONCLUSIONS: In the present report, we demonstrate that an anti-CEA antibody conjugated to a DyLight 650 nm dye clearly labeled colon cancer liver metastases, thereby enabling successful FGS. J. Surg. Oncol. 2016;114:951-958.
BACKGROUND AND OBJECTIVES: Delineation of adequate tumor margins is critical in oncologic surgery, particularly in resection of metastatic lesions. Surgeons are limited in visualization with bright-light surgery, but fluorescence-guided surgery (FGS) has been efficacious in helping the surgeon achieve negative margins. METHODS: The present study uses FGS in a mouse model that has undergone surgical orthotopic implantation (SOI) of colorectal liver metastasis tagged with green fluorescent protein (GFP). An anti-CEA antibody conjugated to DyLight 650 was used to highlight the tumor. RESULTS: The fluorescent antibody clearly demarcated the lesion at deeper tissue depth compared to GFP. Fluorescence of the anti-CEA-DyLight650 showed maximal tumor-to-liver contrast at 72 hr. Fifteen mice underwent bright-light surgery (BLS) versus FGS with GFP versus FGS with anti-CEA-DyLight650. Mice that underwent FGS had a significantly smaller area of residual tumor (P < 0.001) and significantly longer overall survival (P < 0.001) and disease-free survival (P < 0.001). Within the two FGS groups, mice undergoing surgery with anti-CEA-DyLight650 improved survival compared to only GFP labeling. CONCLUSIONS: In the present report, we demonstrate that an anti-CEA antibody conjugated to a DyLight 650 nm dye clearly labeled colon cancer liver metastases, thereby enabling successful FGS. J. Surg. Oncol. 2016;114:951-958.
Authors: Hop S Tran Cao; Sharmeela Kaushal; Cristina A Metildi; Rhiana S Menen; Claudia Lee; Cynthia S Snyder; Karen Messer; Minya Pu; George A Luiken; Mark A Talamini; Robert M Hoffman; Michael Bouvet Journal: Hepatogastroenterology Date: 2012-09
Authors: Ali A Maawy; Yukihiko Hiroshima; Sharmeela Kaushal; George A Luiken; Robert M Hoffman; Michael Bouvet Journal: J Biomed Opt Date: 2013-12 Impact factor: 3.170
Authors: Sharmeela Kaushal; Michele K McElroy; George A Luiken; Mark A Talamini; A R Moossa; Robert M Hoffman; Michael Bouvet Journal: J Gastrointest Surg Date: 2008-07-30 Impact factor: 3.452
Authors: Cristina A Metildi; Chih-Min Tang; Sharmeela Kaushal; Stephanie Y Leonard; Paolo Magistri; Hop S Tran Cao; Robert M Hoffman; Michael Bouvet; Jason K Sicklick Journal: Ann Surg Oncol Date: 2013-08-14 Impact factor: 5.344
Authors: Hannah M Hollandsworth; Hiroto Nishino; Michael Turner; Siamak Amirfakhri; Filemoni Filemoni; Robert M Hoffman; Paul J Yazaki; Michael Bouvet Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155
Authors: Hiroto Nishino; Hannah M Hollandsworth; Norihiko Sugisawa; Jun Yamamoto; Yoshihiko Tashiro; Sachiko Inubushi; Kazuyuki Hamada; Y U Sun; Hyein Lim; Siamak Amirfakhri; Filemoni Filemoni; Robert M Hoffman; Michael Bouvet Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155